Bioretec Ltd, a pioneering company dedicated to advancing biodegradable orthopaedic implants, is moving ahead with the next phase of the commercialization of its innovative RemeOs Trauma Products in ...

Lipella Pharmaceuticals Inc., a clinical-stage biotechnology company focused on innovative therapies for serious diseases with significant unmet needs, announced the completion of dosing for the first ...

GSK plc announced that Japan’s Ministry of Health, Labour and Welfare (MHLW) has approved a regulatory application to extend the indication of Arexvy (respiratory syncytial virus vaccine, recombinant ...

Merck, known as MSD outside of the United States and Canada, announced that the National Medical Products Administration (NMPA) in China has approved Welireg (belzutifan), for the treatment of adult ...

CapeStart introduces MadeAi, a GenAI-enabled platform for life sciences that transforms literature review and other applications: Barcelona, Spain Saturday, November 23, 2024, 17: ...

SOPHiA GENETICS, a cloud-native healthcare technology leader in data-driven medicine, announced the global launch of MSK-IMPACT powered with SOPHiA DDM from the Association for Molecular Pathology ...

Philips introduces next-generation BlueSeal helium-free MRI system, integrated with AI-enabled Smart Reading: Amsterdam, the Netherlands Saturday, November 23, 2024, 13:00 Hrs [IS ...

Zai Lab (Zai Lab) and Pfizer announced a strategic collaboration for the novel antibacterial drug Xacduro (sulbactam-durlobactam) in mainland China. Pfizer’s affiliated companies will be exclusively ...

Zenyaku Kogyo receives Japanese approval for anti-CD20 monoclonal antibody, Rituxan to treat chronic ITP in children: Tokyo Saturday, November 23, 2024, 10:00 Hrs [IST] Zenyaku Ko ...

Leads Biolabs receives US FDA orphan drug designation for anti-PD-L1/4-1BB bispecific antibody, LBL-024 for treatment of neuroendocrine cancer: Nanjing, China Saturday, November 2 ...

LAPIX Therapeutics announces positive results from phase 1 trial of LPX-TI641 for autoimmune diseases treatment: Boston Friday, November 22, 2024, 18:00 Hrs [IST] LAPIX Therapeuti ...

Kura Oncology & Kyowa Kirin ink global strategic collaboration to develop and commercialize ziftomenib in acute leukaemias: San Diego Friday, November 22, 2024, 14:00 Hrs [IST] Ku ...